Asset Details
Do you wish to reserve the book?
Serum IGFBP-2 in systemic sclerosis as a prognostic factor of lung dysfunction
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Serum IGFBP-2 in systemic sclerosis as a prognostic factor of lung dysfunction
Do you wish to request the book?
Serum IGFBP-2 in systemic sclerosis as a prognostic factor of lung dysfunction
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Serum IGFBP-2 in systemic sclerosis as a prognostic factor of lung dysfunction
2021
Overview
Systemic sclerosis (SSc) is a rare connective tissue disease associated with rapid evolving interstitial lung disease (ILD), driving its mortality. Specific biomarkers associated with the progression of this lung disease are highly needed. We aimed to identify specific biomarkers of SSc-ILD to predict the evolution of the disease. For this, we compared prospectively serum levels of several biomarkers associated with lung fibrosis in SSc patients (n = 102), among which SSc-no ILD (n = 63) and SSc-ILD (n = 39), compared to healthy subjects (HS) (n = 39). We also performed a longitudinal study in a subgroup of 28 patients analyzing biomarkers variations and pulmonary function tests over a period of 2 years. Serum level of IGFBP-2 was significantly increased in SSc patients compared to HS, and negatively correlated with pulmonary function (assessed by carbon monoxide transfer coefficient (KCO)) (r = − 0.29, p < 0.01). Two-year longitudinal analysis in a subgroup of 28 SSc patients determined that IGFBP-2 variation was positively correlated with KCO at 2-year follow-up (r = 0.6, p < 0.001). SSc patients with a lower variation of IGFBP-2 (less than 22%) presented significant deterioration of pulmonary function at 2-year follow-up (p < 0.01). ROC curve analysis enabled us to identify that baseline IGFBP-2 > 105 ng/ml was associated with a poor outcome (KCO < 70% predicted) at 2-year follow-up (AUC = 0.75, p < 0.05). We showed for the first time that serum levels of IGFBP-2 might be a prognostic factor of the development of SSc-ILD.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Research,Nature Portfolio
Subject
/ Adult
/ Aged
/ Biochemistry, biophysics & molecular biology
/ Biochimie, biophysique & biologie moléculaire
/ Female
/ Fibrosis
/ Humanities and Social Sciences
/ Humans
/ Insulin-Like Growth Factor Binding Protein 2
/ Insulin-Like Growth Factor Binding Protein 2/blood
/ Lung Diseases, Interstitial/diagnosis
/ Lung Diseases, Interstitial/etiology
/ Male
/ Science
/ Scleroderma, Systemic/complications
